An interventional study of Mind-body medicine group program in Hematologic Neoplasms, sponsored by Universität Duisburg-Essen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Universität Duisburg-Essen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 25th largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2017, is one of 5 with no phase, reaches primary completion later than 6 of the 27 other live ones, and was the 33rd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
CSL Behring · Sites in Germany, United States, Belgium and 8 more countries
Ages 18+
Technical University of Munich · Sites in Germany
Ages 18+
Kura Oncology, Inc. · Sites in Germany, United States, Australia and 14 more countries
Ages 18+
Swedish Orphan Biovitrum · Sites in Germany, United States, Canada and 5 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 25 · Phase 3 13
First in 1995; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 91 across the 50 interventional studies, 450 across the 15 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 65 have an industry lead sponsor. The 10 most frequent:
Universität Duisburg-Essen is the lead sponsor of 85 studies on the registry; 14 are open to participants now.
Universität Duisburg-Essen has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Hematologic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519811Technical University of MunichLLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) | 2026-12-31 |
| NCT03735992Universität Duisburg-EssenMind-body Medicine for Patients With Malignant Hematological Diseases | 2026-12-31 |
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT06645886Kumquat Biosciences Inc.A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | 2027-03 |
| NCT05502887Prof. Dr. Thomas LuftThe Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms | 2027-06-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 65 studies in Hematologic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to investigate the effectiveness of a mind-body group program as a supprtivemanagement strategy for fatigue in patients with malignant hematological diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
Behavioral: Mind-body medicine group program
Treatment as usual.
The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
General Fatigue
Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale
Time frame: week 12
General Fatigue
Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale
Time frame: week 24
Physical Fatigue
Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale
Time frame: week 12
Physical Fatigue
Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale
Time frame: week 24
Reduced Activity
Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale
Time frame: week 12
Reduced Activity
Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale
Time frame: week 24
Reduced Motivation
Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale
Time frame: week 12
Reduced Motivation
Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale
Time frame: week 24
Mental Fatigue
Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale
Time frame: week 12
Mental Fatigue
Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale
Time frame: week 24
Qaulity of life
Functional Assessment of Cancer Therapy - General (FACT-G)
Time frame: week 12
Qaulity of life
Functional Assessment of Cancer Therapy - General (FACT-G)
Time frame: week 24
Depression
Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)
Time frame: week 12
Depression
Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)
Time frame: week 24
Anxiety
Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
Time frame: week 12
Anxiety
Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
Time frame: week 24
Stress
Perceived Stress Scale (PSS)
Time frame: week 12
Stress
Perceived Stress Scale (PSS)
Time frame: week 24
Sleep
Pittsburgh Sleep Quality Index (PSQI)
Time frame: week 12
Sleep
Pittsburgh Sleep Quality Index (PSQI)
Time frame: week 24
Physical activity
Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)
Time frame: week 12
Physical activity
Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)
Time frame: week 24
Fatigability
30-Second Chair Stand Test
Time frame: week 12
Fatigability
30-Second Chair Stand Test
Time frame: week 24
Adverse Events
Number of patients with adverse events
Time frame: week 12
Adverse Events
Number of patients with adverse events
Time frame: week 24
Treatment Expectation
Visual Analogue Scale (VAS)
Time frame: week 0
Treatment Satisfaction
Client Satisfaction Questionnaire (CSQ)
Time frame: week 12
Plan to share: Undecided — Upon reasonable request.
No publications or documents are linked to this record.
Started Sep 2017 (actual). Primary completion is estimated for Dec 2026, 111 months after the start.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 111 months is above that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universität Duisburg-Essen